286371-65-1

Basic information

• Product Name: 4-Chloro-7-methoxy-6-benzyloxyquinazoline
• Synonyms: 4-Chloro-7-methoxy-6-benzyloxyquinazoline;6-(Benzyloxy)-4-chloro-7-methoxyquinazoline;4-chloro-6-benzyloxy-7-methoxyquinazoline;Quinazoline,4-chloro-7-Methoxy-6-(phenylMethoxy)-;(benzyloxy)-4-chloro-7-methoxyquinazoline
• CAS NO: 286371-65-1
• Molecular Formula: C₁₆H₁₃ClN₂O₂
• Molecular Weight: 300.74
• Mol File: 286371-65-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 452.06 °C at 760 mmHg
• Flash Point: 227.198 °C
• Appearance: /
• Density: 1.303
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.639
• Storage Temp.: 2-8°C
• PKA: 0.71±0.30(Predicted)
• CAS DataBase Reference: 4-Chloro-7-methoxy-6-benzyloxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-7-methoxy-6-benzyloxyquinazoline(286371-65-1)
• EPA Substance Registry System: 4-Chloro-7-methoxy-6-benzyloxyquinazoline(286371-65-1)

Safety Data

• Hazardous Substances Data: 286371-65-1(Hazardous Substances Data)

Usage

General Description

4-Chloro-7-methoxy-6-benzyloxyquinazoline is a chemical compound belonging to the quinazoline family. It is a synthetic organic molecule with a molecular formula of C18H15ClN2O2 and a molecular weight of 332.77 g/mol. 4-Chloro-7-methoxy-6-benzyloxyquinazoline is commonly used in research laboratories and pharmaceutical industries as a building block for the synthesis of various biologically active molecules, particularly in the development of potential anticancer and antimalarial drugs. 4-Chloro-7-methoxy-6-benzyloxyquinazoline has also been studied for its potential use as an antifungal and antibacterial agent, making it a subject of interest in the field of medicinal chemistry.

InChI:InChI=1/C16H13ClN2O2/c1-20-14-8-13-12(16(17)19-10-18-13)7-15(14)21-9-11-5-3-2-4-6-11/h2-8,10H,9H2,1H3

Upstream product

• 286371-64-0 6-(benzyloxy)-7-methoxyquinazolin-4(3H)-one 
• 645-08-9 Isovanillic acid 
• 148235-40-9 3-benzyloxy-4-methoxybenzoic acid benzyl ester 
• 634198-01-9 5-benzyloxy-4-methoxy-2-nitrobenzoic acid benzyl ester 
• 634197-80-1 2-amino-5-benzyloxy-4-methoxybenzoic acid benzyl ester 
• 215659-03-3 methyl 5-hydroxy-4-methoxy-2-nitrobenzoate 
• 909912-09-0 benzyl 2-amino-5-(benzyloxy)-4-methoxybenzoic acid 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 286371-64-0 C₁₆H₁₄N₂O₃ 
• 574745-97-4 4-chloro-6-hydroxy-7-methoxyquinazoline 
• 100-39-0 benzyl bromide 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 57535-57-6 methyl 3-(benzyloxy)-4-methoxy-benzoate 

Downstream Products

• 913819-12-2 6-(benzyloxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine 
• 1006890-13-6 6-(benzyloxy)-7-methoxy-N,N-dimethylquinazolin-4-amine 
• 1006889-93-5 6-(benzyloxy)-7-methoxy-4-(pyridin-3-yl)quinazoline 
• 1006890-01-2 7-methoxy-4-pyridin-3-yl-6-(2-quinolin-2-ylethoxy)quinazoline 
• 1188908-25-9 1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)urea 
• 1188908-27-1 4-(3-aminophenoxy)-7-methoxyquinazolin-6-ol 
• 1638151-52-6 (R)-2-((7-methoxy-4-(3-(quinoxaline-2-yloxy)-pyrrolidine-1-yl)-quinazoline-6-yl)-oxy)ethyl 4-methylbenzenesulphonate 
• 184475-35-2 gefitinib 
• 184475-71-6 4-(3-chloro-4-fluorophenylamino)-6-hydroxy-7-methoxyquinazoline 
• 634197-88-9 4-(6-benzyloxy-7-methoxy-quinazolin-4-yl)-piperazine-1-carboxylic acid (4-cyano-phenyl)-amide 

Relevant articles and documents

Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy

As a privileged scaffold, the quinazoline ring is widely used in the development of EGFR inhibitors, while few quinazoline-based MET inhibitors are reported. In our ongoing efforts to develop new MET-targeted anticancer drug candidates, a series of quinaz

Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor of Phosphodiesterase-10

Accurate prediction of absolute protein-ligand binding free energy could considerably enhance the success rate of structure-based drug design but is extremely challenging and time-consuming. Free energy perturbation (FEP) has been proven reliable but is limited to prediction of relative binding free energies of similar ligands (with only minor structural differences) in binding with a same drug target in practical drug design applications. Herein, a Gaussian algorithm-enhanced FEP (GA-FEP) protocol has been developed to enhance the FEP simulation performance, enabling to efficiently carry out the FEP simulations on vanishing the whole ligand and, thus, predict the absolute binding free energies (ABFEs). Using the GA-FEP protocol, the FEP simulations for the ABFE calculation (denoted as GA-FEP/ABFE) can achieve a satisfactory accuracy for both structurally similar and diverse ligands in a dataset of more than 100 receptor-ligand systems. Further, our GA-FEP/ABFE-guided lead optimization against phosphodiesterase-10 led to the discovery of a subnanomolar inhibitor (IC50 = 0.87 nM, ~2000-fold improvement in potency) with cocrystal confirmation.

A simple and highly efficient process for synthesis of Gefitinib and its intermediate

A highly efficient one pot conversion of 4-methoxy-3-benzyloxy-6-nitro benzoate to 6-benzoyloxy-7-methoxy quinazoline-4-one using Fe/acetic acid and formamidine acetate followed by debenzylation of 4-(3-chloro-4-flurophenylamino)-6-benzoyloxy-7-methoxy quinazoline using methanesulfonic acid in chloroform is described. Additionally the desmethyl impurity formation is controlled using oxalyl chloride and DIPEA.